ZUO LI YAO YE(SZ:300181)2024-05-17 13:28Group 1: Investor Relations Activities - The company conducted investor relations activities including site visits and analyst meetings on May 15 and May 17, 2024 [2][3][4] - Key participants included representatives from Shenwan Hongyuan, Pengyang Fund, Dongfang Caifu, and Southern Fund [2][3] Group 2: Product Recognition and Clinical Application - Wuling Capsule has been recognized in 65 clinical guidelines and expert consensus for its efficacy in treating anxiety, depression, and related disorders [2][3] - The product's acceptance is supported by its safety profile and GABA mechanism of action, leading to its use across multiple medical departments [3][4] Group 3: Sales Strategy and Market Coverage - Since 2018, the company has strengthened its marketing team to enhance hospital coverage through a dual model of self-operated and commissioned sales [3][4] - The sales target for Wuling Capsule is to reach a scale of 2 billion CNY, with 90% of revenue currently coming from hospital sales [4][5] Group 4: Product Development and Market Expansion - The company aims to expand the market for Lingze Tablets, targeting a sales goal of 500 million CNY initially, with a long-term goal of 1 billion CNY [5][6] - Lingze Tablets are recognized for their effectiveness in treating benign prostatic hyperplasia and have entered 12 clinical guidelines [4][5] Group 5: Competitive Advantage and Future Plans - The company is focusing on developing traditional Chinese medicine (TCM) products, leveraging its established production capabilities in herbal pieces and formula granules [6][7] - Plans include enhancing OTC market coverage to increase consumer accessibility, aiming for at least 20% of sales from the OTC segment [7]